What question did this study set out to answer?

Assess the efficacy of 177Lu-DOTATATE for treating advanced intracranial meningioma.

June 6, 2026

177 LuLu-DOTATATE for Advanced Intracranial Meningioma: The MOMENTUM-1 (RTOG3523) Study Investigators’ Perspective

Key Points

Assess the efficacy of 177Lu-DOTATATE for treating advanced intracranial meningioma.
Involved the MOMENTUM-1 (RTOG3523) trial based on the clinical application of 177Lu-DOTATATE.
Registry ID provided is NCT06944169, indicating interventional aspects.
Study uses considerations from both MOMENTUM-1 and the LUMEN-1 protocols.
Potential therapeutic benefits have been reported from previous findings.
Expected outcomes are compared against the novel LUMEN-1 study.
Further insights on treatment efficacy are anticipated from ongoing analyses.

Abstract

TO THE EDITOR: As the MOMENTUM-1 (RTOG3523, NCT069441691) study investigators, we have read the article outlining the LUMEN-1 (EORTC-2334-BTG, NCT063261902) study protocol by Albert et al. (13) and the accompanying editorial discussing both the LUMEN-1 and the MOMENTUM-1 studies by

اسأل الذكاء الاصطناعي

Bookmark

Cite This Study

Kurz et al. (Thu,) studied this question.

synapsesocial.com/papers/6a23ba8771a5da9775e7644f https://doi.org/https://doi.org/10.2967/jnumed.126.272153

اسأل الذكاء الاصطناعي

Bookmark